Opioids Research to Practice

CRIT/FIT 2015

May 2015

Daniel P. Alford, MD, MPH, FACP, FASAM
Associate Professor of Medicine
Assistant Dean, Continuing Medical Education
Director, Clinical Addiction Research and Education (CARE) Unit







Case

- 32 yo female brought in after "heroin overdose"
- Brisk response to IV naloxone 0.4 mg
- Re-sedation after 1 hr requiring repeat naloxone
- Arm cellulitis at injection drug use site
- Admitted for "drug overdose", "persistent altered mental status" and "arm cellulitis"

Opioids

CH3-O-C-3 N-CH₃ CH3-O-

Diacetylmorphine (Heroin)

Natural (Opiates) and Semisynthetic

Hydrocodone

HO V 917 N-CH₃ Odeine and Morphine

Hydromorphone

Oxymorphone

Oxycodone

Synthetic


Methadone

Meperidine


Fentanyl

Why is heroin so pleasurable?

- Heroin is highly lipid soluble
- Crosses blood brain barrier within 15 seconds="rush"
- After IV administration 68% heroin in brain compared to <5% of morphine
- Within 30 minutes metabolized to morphine
- HEROIN is a prodrug of MORPHINE



Natural History of Opioid Use Disorder



Conflicting Priorities...

AIDS PLEDGE WALK Sunday, June 2 Boston Common Suggested minimum pledge: \$2.00 per kilometer or \$20.00.Please pre-pay. For security purposes, we prefer that pledges be collected in the form of	Walker's name street address city/state/zip telephone (day) (eve) My fundraising goal is: \$200 T-shirt \$500 Sweatshirt \$750 Canvas attaché \$1,500 New Balance athletic shoes \$2,500 Polaroid Impulse camera and film
checks made payable to AIDS Action Committee. Contributions are tax- deductible. Thank you! Sponsor's name Address/city/state/zip	Amount Amount pledged paid
Spurious a name Production of the Spurious Conference of the Spurious Confe	
3 TO HURSE IT	+ CHARSE.
4	· · · · · · · · · · · · · · · · · · ·
5 MORMAH	IS OR MAVE TO LEAVE
THE HOSPITAL GODS	HOHITOR I PROMISE YOU
8 7 WILL RETURN AT	DINHER TIME.
9 I JUST HAVE TO G	
10	
11	P.S.
12	SORRY THAT I LEFT
	OT I KNOW YOU WOOLD HAVE
14	TOT LET ME SO SEE XOO
15	AT DINHER TIME PROMISE.
16	
17	-1
185ps/96abone note found at	
	o aware.
20	N Keellisoon


Case continued

Substance use history

- ½ gram of heroin/day
- Intranasal use for 6 months then IV for 7 years
- Had been in recovery for 2 years by going to NA but relapsed 3 months ago
- Denies sharing needles
- History of 10 detox's, no maintenance treatment
- No other drug, alcohol or tobacco use
- HIV and hepatitis C negative
- Unemployed elementary school teacher
- Lives with husband (in recovery) and 2 young children
- Now complaining of opioid withdrawal
 - How will you assess and treat her?

Which is **NOT** a sign of opioid withdrawal?

- 1. Vomiting
- 2. Diarrhea
- 3. Pinpoint pupils
- 4. Rhinorrhea
- 5. Lacrimation
- 6. Piloerection




Opioid Withdrawal Assessment

Grade	Symptoms / Signs	
0	Anxiety, Drug Craving	
1	Yawning, Sweating, Runny nose, Tearing eyes, Restlessness Insomnia	
2	Dilated pupils, Cooseflesh, Muscle twitching & shaking, Muscle & Joint acries, Loss of appetite	
3	Nausea, extreme restlessness, elevated blood pressure, Heart rate > 100, Fever	
4	Vomiting / dehydration, Diarrhea, Abdominal cramps, Curled-up body position	

Clinical Opiate Withdrawal Scale (COWS): pulse, sweating, restlessness & anxiety, pupil size, aches, runny nose & tearing, GI sx, tremor, yawning, gooseflesh (score 5-12 mild, 13-24 mod, 25-36 mod sev, 36-48 severe)

How is acute opioid withdrawal treated on your inpatient service?

- 1. Clonidine
- 2. Methadone
- 3. Buprenorphine
- 4. Don't know
- 5. Other



Inpatient Goals

- Prevent/treat acute opioid withdrawal
 - Inadequate treatment may prevent full treatment of medical/surgical condition
- Do not expect to <u>cure</u> opioid dependence during this hospital stay
 - Withholding opioids will not cure patient's addiction
 - Giving opioids will not worsen patient's addiction
- Diagnose and treat medical illness
- Initiate substance abuse treatment referral

Inpatient Goals

- Methadone is the best choice!
 or buprenorphine (more expensive)
- Other
 - Clonidine (hyperadrenergic state)
 - + NSAIDS (muscle cramps and pain)
 - + Benzodiazepines (insomnia)
 - + Dicyclomine (abdominal cramps)
 - + Bismuth subsalicylate (diarrhea)

- Assess signs and symptoms of acute opioid withdrawal
- Reassure patient
- Discuss specific dose and goals openly with patient and nursing staff
- Don't use heroin: methadone conversions

- Start with 20 mg of methadone
- Reassess q 2-3 hours, give additional 5-10 mg until withdrawal signs abate
- Do not exceed 40 mg in 24 hours
- Monitor for CNS and respiratory depression

- On following day, give total dose QD
- Goal is to alleviate acute withdrawal
- Patient will continue to crave opioids
- Discuss taper vs maintained dose w/ pt daily
- Referral for long-term substance abuse treatment

- Maintained dose option
 - Give same dose each daily including day of discharge
 - Allows 24-36 hour withdrawal-free period after d/c
- Tapered dose option
 - If patient requests a taper, decrease by 5 mg per day and stop taper if patient requests it
 - Don't prolong hospitalization to complete taper
- Don't give a prescription for methadone


Case continued

Hospital course

- Arm Cellulitis treated with IV Vancomycin
- Opioid withdrawal
 - ■Day 1 Methadone 20 mg
 - Day 2
 - Very anxious, demanded increase in methadone dose
 - Was off the floor for 2 hours
 - Repeat urine drug test was positive for "opiates"

All of the following are possible explanations for her <u>opiate positive</u> drug test <u>EXCEPT</u>?

- Illicit opioid (heroin) use during hospitalization
- 2. Heroin use prior to admission
- Hydromorphone (Dilaudid) given for pain last night
- 4. Methadone given during hospitalization



Opioids

CH3-O-C-3 N-CH₃ CH3-O-

Diacetylmorphine (Heroin)

Natural (Opiates) and Semisynthetic

Hydrocodone

HO V 917 N-CH₃ Odeine and Morphine

Hydromorphone

Oxymorphone

Oxycodone

Synthetic

Methadone

Meperidine

Fentanyl

Case continued

6 months later

- She presents to your primary care clinic requesting treatment for her heroin addiction
- She has been using heroin since the day she left the hospital

Case continued

Recommended options from primary care

- Narcotics Anonymous (NA)
- Clonidine + NSAID + benzodiazepine + ...
- Naltrexone (po or injectable)
- Buprenorphine maintenance (if waivered)
- Overdose prevention education and naloxone
- Referral
 - Detoxification program
 - Needle exchange
 - Acupuncture
 - Outpatient counseling
 - Methadone maintenance
 - Buprenorphine maintenance (if not waivered)

Opioid Detoxification Outcomes

- Low rates of retention in treatment
- High rates of relapse post-treatment
 - < 50% abstinent at 6 months</p>
 - < 15% abstinent at 12 months</p>
 - Increased rates of overdose due to decreased tolerance

O'Connor PG JAMA 2005 Mattick RP, Hall WD. Lancet 1996 Stimmel B et al. JAMA 1977

Reasons for Relapse

- Protracted abstinence syndrome
 - Secondary to derangement of endogenous opioid receptor system
 - Symptoms
 - Generalized malaise, fatigue, insomnia
 - Poor tolerance to stress and pain
 - Opioid craving
- Conditioned cues (triggers)
- Priming with small dose of drug

Pharmacotherapy

Goals

- Alleviate physical withdrawal
- Opioid blockade
- Alleviate drug craving
- Normalized deranged brain changes and physiology

Some options

- **Naltrexone** (opioid antagonist)
- Methadone (full opioid agonist)
- **Buprenorphine** (partial opioid agonist)

Medication-Assisted Therapies — Tackling the Opioid-Overdose Epidemic

Nora D. Volkow, M.D., Thomas R. Frieden, M.D., M.P.H., Pamela S. Hyde, J.D., and Stephen S. Cha, M.D.

The rate of death from overdoses of prescription opioids in the United States more than quadrupled between 1999 and 2010 (see graph), far exceeding the combined death toll from cocaine and heroin

scription opioids were involved in 16,651 overdose deaths, whereas heroin was implicated in 3036. Some 82% of the deaths due to those due to heroin were classiremainder being attributed predominantly to suicide or "undetermined intent."

visits and substance-abuse treatment admissions related to prescription opioids have also increased markedly. In 2007, prescription-opioid abuse cost insurers an estimated \$72.5 billion a substantial increase over previous years.2 These health and

overdoses.1 In 2010 alone, pre- economic costs are similar to those associated with other chronic diseases such as asthma and HIV infection.


prescription opioids and 92% of Department of Health and Human Services (HHS) to deem prefied as unintentional, with the scription-opioid overdose deaths an epidemic and prompted multiple federal, state, and local actions.2 The HHS efforts aim to si-Rates of emergency department multaneously reduce opioid abuse response.2 Like other chronic disand safeguard legitimate and appropriate access to these medications. HHS agencies are im- refractory to cure, but effective plementing a coordinated, comprehensive effort addressing the ery are possible. Fortunately, clikey risks involved in prescriptiondrug abuse, particularly opioidrelated overdoses and deaths.

These efforts focus on four main objectives: providing prescribers with the knowledge to improve their prescribing decisions and the ability to identify patients' problems related to opioid abuse, reducing inappropriate access to opioids, increasing access to effective overdose treatment, and providing substance-abuse treatment These alarming trends led the to persons addicted to opioids.

> A key driver of the overdose epidemic is underlying substanceuse disorder. Consequently, expanding access to addictiontreatment services is an essential component of a comprehensive eases such as diabetes and hypertension, addiction is generally treatment and functional recovnicians have three types of medication-assisted therapies (MATs) for treating patients with opioid

The New England Journal of Medicine

Opioid Agonist Treatment (OAT)



Acute use

Chronic use

Naltrexone

- Pure opioid antagonist
- Oral naltrexone
 - Well tolerated, safe
 - Duration of action 24-48 hours
 - FDA approved 1984
- Injectable naltrexone (Vivitrol[®])
 - IM injection (w/ customized needle) once/month
 - FDA approved 2010
 - Patients must be opioid free for a minimum of 7-10 days before treatment

Oral Naltrexone

- 10 RCTs ~700 participants to naltrexone alone or with psychosocial therapy compared with psychosocial therapy alone or placebo
 - No clear benefit in treatment retention or relapse at follow up
- Benefit in highly motivated patients
 - Impaired physicians > 80% abstinence at 18 months

Injectable Naltrexone (XR-NTX)

- Multicenter (13 sites in Russia-OAT unavailable) DB RPCT 24 weeks
- 250 individuals with opioid dependence randomized to XR-NRT vs placebo
- All offered biweekly individual drug counseling
- Funded by pharmaceutical company Alkermes

	XR-NTX (n=126)	Placebo (n=124)
Primary endpoint		
Proportion of weeks of confirmed abstinence	90·0% (69·9 to 92·4)	35·0% (11·4 to 63·8)
Patients with total confirmed abstinence	45 (35·7%, 27·4 to 44·1)	28 (22·6%, 15·2 to 29·9)
Secondary endpoint		
Proportion of self-reported opioid-free days over 24 weeks	99-2% (89-1 to 99-4)	60·4% (46·2 to 94·0)
Craving: mean change in VAS score from baseline	-10·1 (-12·3 to -7·8)	0·7 (-3·1 to 4·4)
Number of days of retention	>168‡	96 (63 to 165)

Methadone Hydrochloride

- Full opioid agonist
- PO onset of action 30-60 minutes
- Duration of action
 - 24-36 hours to treat opioid addiction
 - 6-8 hours to treat pain
- Proper dosing for opioid addiction
 - 20-40 mg for acute withdrawal
 - > 80 mg for craving, "opioid blockade"

Methadone Maintenance Over 45 Years of Experience...

A Medical Treatment for

Diacetylmorphine (Heroin) Addiction

A Clinical Trial With Methadone Hydrochloride

Vincent P. Dole, MD, and Marie Nyswander, MD

A group of 22 patients, previously addicted to diacetylmorphine (heroin), have been stabilized with oral methadone hydrochloride. This medication appears to have two useful effects: (1) relief of narcotic hunger, and (2) induction of sufficient tolerance to block the euphoric effect of an average illegal dose of diacetylmorphine. With this medication, and a comprehensive program of rehabilitation, patients have shown marked improvement; they have returned to school, obtained jobs, and have become reconciled with their families. Medical and psychometric tests have disclosed no signs of toxicity, apart from constipation. This treatment requires careful medical supervision and many social services. In our opinion, both the medication and the supporting program are essential.

ough review of evidence available in 1957,1 concluded that "The advisability of establishing clinics or some equivalent system to dispense opiates to addicts cannot be settled on the basis of objective facts. Any position taken is necessarily based in part on opinion, and on this question opinions are divided." With respect to previous trials of maintenance treatment, the Council found that "Assessment of the operations of the narcotic dispensaries between 1919 and 1923 is difficult because of the paucity of published material. Much of the small amount of data that is available is not sufficiently objective to be of great value in formulating any clear-cut opinion of the purpose of the clinics, the way in which they operated, or the results attained." No new studies bearing on the question



Methadone Treatment Marks 40 Years

Bridget M. Kuehn

ORTY YEARS AND COUNTLESS Political firestorms after it was first introduced, methadone maintenance for the treatment of opioid addiction remains a standard therapy in the field of addiction treatment.

The publication on August 23, 1965, of positive results from a small clinical trial of methadone as a treatment for heroin addiction in *JAMA* marked a sea change in the treatment of addiction (Dole and Nyswander. *JAMA*. 1965; 193:646-650). The study, conducted at Rockefeller University in New York City by Vincent P. Dole, MD, and the late Marie E. Nyswander, MD, suggested that a medication could be used to control the cravings and withdrawal that often lead to relapse in individuals with opioid addiction who attempt to quit.

The work, along with subsequent research by Dole, an endocrinologist, Nyswander, a psychiatrist, and colleagues established the concept of opioid addiction as a chronic disease, similar to diabetes, that as such required

now head of the Laboratory of the Biology of Addictive Diseases at Rockefeller University, explained that work conducted by the group in 1964 and published in 1966 established that methadone blocked the effects of heroin and stabilized patients, who prior to treatment oscillated between feeling



done treatment, the ap always struggled for accep the forces of public opini tics. "There is a stigma a tions, addicts, and—sadly providers," said Kreek, a supporter of the methado

"THE FARM"


Methadone maintenance resented a reversal of the tapproach to treating drusaid David F. Musto, MD turer at Yale and expert policy. A 1919 Supreme sion had established thalone did not justify physical policies, some physicians had acting opioids to treat indopioid addiction.

The Drug Enforcement tion, in fact, considered Dillegal and had threatened him prior to the 1965 pub defy the US government wa litical courage," said Jeror who became the first natio

JAMA 2005

JAMA 1965


METHADONE IN OTPS FOR OUD: 2009-2013



Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey of Substance Abuse Treatment Services, 2009 to 2013.


Methadone Maintenance Still controversial...

"I don't believe in methadone...substituting one drug for another...liquid handcuffs..."



Methadone Maintenance Dosing





SOURCE: Ball and Ross 1991, p. 248.

* Adapted from a study of 407 methadone maintenance patients.






FIGURE 7.1. Impact of methadone maintenance treatment on intravenous drug use for 388 male methadone patients in six programs.

Effects of Psychosocial Services



What is the single best question to assess a patient's success on methadone maintenance treatment?

- 1. Are you using drugs?
- 2. Are you on "take home" doses?
- 3. Are you compliant with methadone treatment?
- 4. How long have you been on methadone treatment?



Methadone Maintenance Treatment Highly Structured

- Daily nursing assessment
- Weekly individual and/or group counseling
- Random supervised drug testing
- Psychiatric services
- Medical services
- Methadone dosing
 - Observed daily ⇒ "Take homes"

In a Comprehensive Rehabilitation Program...

- Increases overall survival
- Increases treatment retention
- Decreases illicit opioid use
- Decreases hepatitis and HIV seroconversion
- Decreases criminal activity
- Increases employment
- Improves birth outcomes

Methadone Maintenance Limitations

- Highly regulated Narcotic Addict Treatment Act 1974
 - Created methadone clinics (Opioid Treatment Programs)
 - Separate system not involving primary care or pharmacists
- Limited access
- Inconvenient and highly punitive
- Mixes stable and unstable patients
- Lack of privacy
- No ability to "graduate" from program
- Stigma

DATA 2000 and Buprenorphine

2000: Drug Addiction Treatment Act (DATA) 2000

 Allows <u>qualified physician</u> to prescribe <u>scheduled III - V</u>, narcotic <u>FDA approved</u> for opioid maintenance or detoxification treatment limit <u>30 patients per practice</u>

2002: Suboxone and Subutex FDA approved

2005: Limit to 30 patients per physician

2007: Limit to 100 patients per physician after 1 year

Physician Qualifications


The <u>physician</u> is licensed under State law and "<u>qualified</u>" based on <u>one</u> of the following:

- Certified in Addiction Psychiatry or Medicine
- Completed <u>eight hours</u> of training
 - List of trainings: www.buprenorphine.samhsa.gov
 - Online training: www.buppractice.com


Buprenorphine

- Buprenorphine (Subutex or generic) "mono"
- Buprenorphine + naloxone (Suboxone) "combo"
 - Schedule III
 - Sublingual tablets, film
 - Treatment of opioid dependence
 - High receptor affinity
 - Slow dissociation
 - Ceiling effect for respiratory depression

BUPRENORPHINE FOR OUD: 2003-2013



Buprenorphine Maintenance versus Taper



Buprenorphine Efficacy

- Studies (RCT) show buprenorphine more effective than placebo and equally effective to moderate doses (80 mg) of methadone on primary outcomes of:
 - Abstinence from illicit opioid use
 - Retention in treatment
 - Decreased opioid craving

Johnson et al. NEJM 2000

Fudala PJ et al. NEJM 2003


Kakko J et al. Lancet 2003

Methadone vs Buprenorphine

9 OTPs **n=1,267**

RCT buprenorphine vs methadone

6 month retention



Opioid Maintenance Treatment and Acute Pain Management

- Patients on opioid maintenance treatment (i.e. methadone or buprenorphine) have less pain tolerance then matched controls
- Patients who are physically dependent on opioids (i.e. methadone or buprenorphine) must be maintained on daily equivalence before ANY analgesic effect is realized with opioids used for acute pain management
- Opioid analgesic requirements are often higher due to increased pain sensitivity and opioid cross tolerance